Criticism of study planning: patient-reported endpoints are often collected far too briefly


3 March 2022 - A striking example: abemaciclib in advanced breast cancer. Shortened data on quality of life, symptoms and side effects impair the early benefit assessment.

Abemaciclib in combination with fulvestrant is used to treat post-menopausal women with hormone receptor-positive, HER2 negative locally advanced or metastatic breast cancer. After the expiry of a decision by the Federal Joint Committee (G-BA), the IQWiG has again assessed its additional benefit - with mixed results.

Read IQWiG press release {German]

Michael Wonder

Posted by:

Michael Wonder